Biology and physiology of Calbindin-D9k in female reproductive tissues: Involvement of steroids and endocrine disruptors by Choi, Kyung-Chul et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Review
Biology and physiology of Calbindin-D9k in female reproductive 
tissues: Involvement of steroids and endocrine disruptors
Kyung-Chul Choi1, Peter CK Leung1 and Eui-Bae Jeung*2
Address: 1Department of Obstetrics and Gynecology, British Columbia Children's and Women's Hospital, Child and Family Research Institute, 
University of British Columbia, Vancouver, BC V6H 3V5 Canada and 2Laboratory of Veterinary Biochemistry and Molecular Biology, College of 
Veterinary Medicine and Research Institute of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, 361-763 Republic of 
Korea
Email: Kyung-Chul Choi - kchoi@cw.bc.ca; Peter CK Leung - peleung@interchange.ubc.ca; Eui-Bae Jeung* - ebjeung@chungbuk.ac.kr
* Corresponding author    
Abstract
Although Calbindin-D9k (CaBP-9k), a cytosolic calcium binding protein which has calcium binding
sites, is expressed in various tissues, i.e., intestine, uterus, and placenta, potential roles of this gene
and its protein are not clearly understood. Uterine CaBP-9k may be involved in controlling
myometrial activity related with intracellular calcium level and is not under the control of vitamin
D despite the presence of vitamin D receptors. But, it is under the control of the sex steroid
hormones, estrogen (E2) and progesterone (P4), in female reproductive systems including the
uterus and placenta. Thus, in this review, we summarize recent research literature in regards to
the expression and regulation of CaBP-9k in mammals and introduce the research data of recent
studies by us and others.
Introduction
A 9-kilodalton cytosolic calcium-binding protein termed
as Calbindin-D9k (CaBP-9k) belongs to a family of intra-
cellular proteins which have high affinities for calcium,
and has two calcium binding domains [1]. The full-length
cDNA encoding the human CaBP-9k has been cloned
using reverse transcription/PCR, which includes coding
region of 79 amino acids, 57 nucleotides 5'- and 159
nucleotides 3'-non-coding region, and a poly(A) tail (total
600 nucleotides in length) [2]. Further, our study revealed
that this gene spans about 5.5-kb and is localized on the
X-chromosome, consists of three exons and carries four
Alu repeats [3]. In addition to its genomic structure, a
sequence of 50 nucleotides downstream from the pro-
moter showed an extensive homology to the estrogen
response element (ERE) at the same location within the
rat calbindin-D9k gene, suggesting that a two-nucleotide
change within this region in human causes the gene to
lack expression in human uterus and placenta [3].
It has been demonstrated that CaBP-9k is expressed in
diverse mammalian tissues, i.e., intestine, uterus, kidney,
and bone [4-7]. The functional role of CaBP-9k is
involved in intestinal calcium absorption and its gene is
regulated at the transcriptional or post-transcriptional
level by 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), a
hormonal form of vitamin D [8,9]. This hormonal form
caused a parallel increase in CaBP-9k mRNA and intesti-
nal absorption of calcium in rats [10]. In addition, uterine
CaBP-9k may be involved in controlling myometrial
activity related with intracellular calcium level [6], but an
exact role of CaBP-9k in the uterus is still under investiga-
tion by us and a few of other research groups. Recently, we
demonstrated that uterine CaBP-9k is responsive to exog-
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enous estrogen (E2) and can be a biomarker for environ-
mental estrogenic chemicals, so called as "endocrine
disruptors" in rat models [11-15]. Thus, in this review, we
summarize recent research literature in regards to the
expression and regulation of CaBP-9k in mammals and
introduce updated research results by us and others.
Uterine expression of CaBP-9k
It has been demonstrated that CaBP-9k is mainly
expressed in the endometrial stroma and myometrium of
the uterus in non-pregnant rats [16,17], whereas this gene
is translocated into the epithelium of the uterus in preg-
nant rats [18]. However, it has been shown that the CaBP-
9k is only expressed in the luminal and glandular epithe-
lium of the endometrium, not in the myometrium and in
the stromal cells of the endometrium in non-pregnant
cows [19]. In contrast to the regulation of CaBP-9k in the
intestine, CaBP-9k gene is not under the control of vita-
min D in the uterus despite the presence of vitamin D
receptors in this tissue. This gene appears to be under the
control of the sex steroid hormones [17,20,21].
There is a strong body of evidence that CaBP-9k is regu-
lated by sex steroid hormones in the uterus of rats. Treat-
ment of 21-day-old rats with E2 resulted in an increase in
the expression of CaBP-9k mRNA up to 300-fold and its
mRNA was shown to fluctuate in the uterus of rats during
estrous cycle, where serum E2 level was also under fluctu-
ation [22]. Although the expression of CaBP-9k mRNA is
not detectable at diestrus when E2 level is at the lowest,
this mRNA increases at proestrus and reaches the highest
level at estrus in response to the rise in plasma E2 and
then decreases at metestrus in the uterus of rats [20,22]. In
addition, E2-dependent regulation of CaBP-9k gene was
demonstrated. i.e., CaBP-9k synthesis decreased drasti-
cally in the uterus of ovariectomized rats, whereas it was
greatly enhanced by low physiological doses of E2 in a
dose-dependent manner by CaBP-radioimmunoassay
(RIA) [17]. This E2-dependent regulation of CaBP-9k gene
was also approved in the uterus of mature ovariectomized
and immature rats by slot and Northern blot analysis
[23,24]. In estrogen-primed ovariectomized rats, proges-
terone (P4) inhibited E2-induced CaBP-9k gene expres-
sion, which was completely abolished by co-
administration of RU486, a P4 antagonist [20]. In the
pregnant rats, P4 was shown to be responsible for down-
regulation of CaBP-9k gene in the uterus during early
pregnancy [25]. In the ovariectomized (OVX) gilts, E2
treatment induced an increase in CaBP-9k mRNA level,
whereas P4 administration to ovariectomized pigs
decreased CaBP-9k mRNA levels [26]. Recently, we dem-
onstrated that CaBP-9k mRNA and protein are domi-
nantly expressed during luteal phase, indicating that P4
may play an important role in the up-regulation of CaBP-
9k gene in the porcine uterus during luteal phase, which
is unlike the condition in the rat uterus (Fig. 1) [27]. In
this study, the porcine CaBP-9k may be dominantly
expressed in the epithelium and glandular structure of the
porcine uterus during luteal phase, suggesting that CaBP-
9k gene may also be differentially regulated during this
cycle presumably by steroid hormones, especially up-reg-
ulated P4 level in this tissue [27]. In addition, a positive
role of P4 on the expression of CaBP-9k has been demon-
strated in the bovine uterus, which indicates that the
expression of CaBP-9k was greatest during P4-dominated
luteal phase of the bovine estrous cycle [19].
In contrast to the uterus of rats, the expression of CaBP-9k
gene is not under strict E2 regulation in the uterus of mice.
The uterus of mice has been demonstrated to express
CaBP-9k and its level increases in this tissue during early
pregnancy and implantation [28,29]. CaBP-9k mRNA is
expressed in the endometrial epithelia, both luminal and
glandular, in the uterus at the time of implantation, and
in the luminal, but not in the glandular, epithelia on early
pregnancy (day 5 of pregnancy). P4 enhanced CaBP-9k
mRNA expression in the uterus, whereas E2 did not in the
oophorectomized adult mice [28]. A higher expression of
CaBP-9k mRNA was observed in the uterus of mice at die-
strus and metestrus, whereas only basal level of its expres-
Porcine CaBP-9k mRNA expression in the endometrium and  whole uterus during an estrus cycle Figure 1
Porcine CaBP-9k mRNA expression in the endometrium and 
whole uterus during an estrus cycle. To investigate a role of 
CaBP-9k in the tissue compartment of the pig uterus, the 
expression levels of CaBP-9k mRNA (A) and protein (B) 
were analyzed by Northern blot and immunoblot analyses. 
[Reproduced with permission from Yun S-M, Choi KC, Kim 
IH, An BS, Lee GS, Hong EJ, Son JH, Oh GT, Jeung E-B 2004 
Calbindin-D9k mRNA expression and regulation during estrus 
cycle in the pig uterus. Mol Reprod Dev 67: 251\endash 256]
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sion at proestrus and estrus, and E2 alone did not induce
uterine CaBP-9k mRNA in this study [29]. Taken together,
these results suggest the complex hormonal regulation of
CaBP-9k in the uterus of different species. To date, there
was no evidence that CaBP-9k gene may be regulated by
E2 in female reproductive tract of mice. In the recent
study, we demonstrated that RU486, a P4 antagonist,
induced a significant decrease in CaBP-9k mRNA expres-
sion, whereas tamoxifen and ICI 182,780, an E2 antago-
nists, had no effect on CaBP-9k mRNA expression,
suggesting that P4, not E2, is a key regulator of CaBP-9k
mRNA expression during late pregnancy and lactation in
the uterus of mice [30].
The mechanism involved in the regulation of uterine
CaBP-9k gene by steroids is relatively well understood in
rats. In the uterus of rats, estrogen is known to up-regulate
and progesterone down-regulate the expression of CaBP-
9k gene during estrous cycle and early pregnancy
[20,22,24,25]. The expression level of CaBP-9k mRNA
fluctuates during the estrous cycle, but shows very differ-
ent expression pattern in the uterus of between rats and
mice as abovementioned [29]. The mechanism of distinct
regulation of CaBP-9k gene between the rat and mouse is
not clear at the moment. The effect of E2 on the regulation
of CaBP-9k appears to be mediated through an imperfect
estrogen-responsive-like element (ERE) identified in the
intron A of mouse CaBP-9k gene [8,24]. The regulation of
this gene is known to be mediated by an E2 response ele-
ment located at the first intron of rat CaBP-9k gene [31].
Recently, cloning of intron A of the mouse CaBP-9k gene
have revealed single-base difference in the ERE compared
to that of the rat [32]. This may partially explain the
observed difference in the hormonal regulation of CaBP-
9k gene in the uterus of between rats and mice. In addi-
tion, a distinct regulation of porcine CaBP-9k gene in the
uterus is explained by no presence of a functional ERE
within intron A region [26]. However, we can not rule out
the possibility of involvement of other unknown cell-, tis-
sue-, and species-specific factors in the CaBP-9k gene
expression. This idea is supported by the finding that E2
regulation of CaBP-9k gene in rats was only uterine-spe-
cific and this does not occur in the intestine [17].
Although the putative ERE failed to bind to the estrogen
receptor (ER) from the mouse uterus, we isolated mouse
genomic clones of the CaBP-9k gene and analyzed their
expression in the mouse uterus [33]. In addition, we
found a promoter region of CaBP-9k gene containing the
putative progesterone response element (PRE) and its
expression was stimulated by P4, suggesting that the
mouse uterine CaBP-9k gene is expressed under the con-
trol of a PRE [33]. In the recent study, we demonstrated
that P4 and PR may be a dominant factor in the regulation
of CaBP-9k and E2 and ERα can also influence the expres-
sion of CaBP-9k gene via an indirect pathway in the uterus
of immature mice [34]. Currently, endocrine disruptor-
induced expression of CaBP-9k mRNA and protein was
reversed or abolished by pretreatment with RU486 or ICI
182,780, suggesting that these synthetic chemicals may
have both progestogenic and estrogenic properties by act-
ing through PR or ER in the induction of uterine CaBP-9k
mRNA and protein in the uterus of immature mice [35].
Uterine induction of CaBP-9k as a biomarker for 
endocrine disruption
Endocrine disruptors (EDs) are environmental chemicals
that interfere with physiological systems, adversely affect-
ing hormone balance (endocrine system) or disrupting
normal function in the organs that hormones regulate or
modulate, for example, female and male reproductive sys-
tem [36]. Representative example of suspected environ-
mental estrogenic EDs includes the drugs which have
been specifically designed to treat hormone imbalance in
humans. These estrogenic compounds, including octyl-
phenol (OP), nonylphenol (NP), bisphenol A (BPA), and
methoxychlor (MXC), can also be transferred through the
placenta to the fetus and through breast milk to infants
[11,13,37]. Screening methods to detect endocrine dis-
rupters have been evaluated by many groups, i.e. the
receptor binding assay, reporter gene assay, and immature
Induction of uterine CaBP-9k protein by estrogenic com- pounds, i.e., OP, NP and BPA was assessed in a dose-depend- ent manner at 24 h after final injection by immunoblot  analysis Figure 2
Induction of uterine CaBP-9k protein by estrogenic com-
pounds, i.e., OP, NP and BPA was assessed in a dose-depend-
ent manner at 24 h after final injection by immunoblot 
analysis. Data are presented as the mean ± SD. a; significantly 
different compared with vehicle at P < 0.05. [Reproduced 
with permission from An B-S, Choi KC, Kang SK, Hwang 
WS, Jeung EB 2003 Novel Calbindin-D9k protein as a useful 
biomarker for environmental estrogenic compounds in the 
uterus of immature rats. Reprod Toxicol 17: 311–319]Reproductive Biology and Endocrinology 2005, 3:66 http://www.rbej.com/content/3/1/66
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rat uterotrophic assay. The reporter gene assay has many
benefits as a promising prescreening procedure, because
this assay could be performed as a high throughput
screening process to detect an endocrine disruptor from
thousands of chemicals and no use of experimental ani-
mals is required [38]. To screen estrogenic chemicals in
the induction of endocrine disruption, genetically sensi-
tive animal models, mice and rats, should be developed.
Efforts to identify the mechanisms of endocrine disrup-
tion by estrogenic chemicals need to be supported for
optimal test methods for thousands of potential chemi-
cals in reproductive development and function [39]. Thus,
we have recently established a sensitive method to detect
CaBP-9k mRNA and protein using immature rats, which
can be used as a biomarker for endocrine disruptors, thus,
we introduce our current results in regard to estrogenic
effect of endocrine disruptors in the uterus of immature
rats [12]. Among the assays for the estrogenic activity of
chemicals, an assay to detect an endogenous gene expres-
sion that measures estrogen-induced changes either in
cultured cells or in selected tissues from exposed animals
has been proposed and is widely being used. In our previ-
ous study, we demonstrated that phthalate esters exhibit a
weak estrogenic activity in vitro assay at high concentra-
tions. Although phthalates resulted in an increase in MCF-
7 cell proliferation by estrogenic effect, they could not
induce CaBP-9k expression in vivo system following oral
treatments, assuming that these phthalates are easily
metabolized to inactive forms in vivo system. These results
suggest that a conflict may exist in estrogenic effect by var-
ious phthalates between in vitro and in vivo models related
to the expression of CaBP-9k [40].
The expression levels of CaBP-9k mRNA and protein are
strongly up-regulated by estrogenic compounds (OP, NP
and BPA) and E2 itself in the uterus of immature rats (Fig.
2), indicating that CaBP-9k can be a useful biomarker for
detection of the estrogenicity of putative estrogenic com-
pounds. Thus, regarding to risk assessment, we propose
that CaBP-9k mRNA and protein assay in the immature
rat uterus can be a very sensitive and powerful tool to
identify compounds with estrogenic activity when used in
combination with classical assays [11,23]. Treatments of
dams with OP, NP and BPA resulted in an increase of
CaBP-9k mRNA and protein in maternal and fetal uteri
(Fig. 3) of immature rats [13]. These results demonstrate
that maternally injected estrogenic compounds resulted
in an increase of CaBP-9k mRNA and/or protein in the
maternal tissues (uterus and placenta) and fetal uterus
during late pregnancy, suggesting that placenta may not
be a reliable barrier against these estrogenic compounds
for fetal health [13]. The uterus is a highly estrogen-
responsive tissue, which can be measured through
changes in CaBP-9k expression. In addition, we investi-
gated the potential for estrogenic compounds, OP, NP,
Effect of endocrine disruptors on the induction of CaBP-9k  mRNA in neonatal uterus Figure 4
Effect of endocrine disruptors on the induction of CaBP-9k 
mRNA in neonatal uterus. RT-PCR/Southern blot analysis for 
CaBP-9k mRNA on day 6 of lactation was performed as pre-
viously described. The values represent means ± SD (n = 5). 
a, P < 0.05 vs. vehicle (VE). [Reproduced with permission 
from Hong E-J, Choi KC, Jung YW, Leung PCK, Jeung E-B 
2004 Transfer of maternally injected endocrine disruptors 
through breast milk during lactation induces neonatal Calbin-
din-D9k in the rat model. Reprod Toxicol 18: 661–668]
Induction of CaBP-9k mRNA expression in fetal uterus by  estrogenic compounds Figure 3
Induction of CaBP-9k mRNA expression in fetal uterus by 
estrogenic compounds. The values represent means ± SD. a, 
P < 0.05 vs. vehicle. [Reproduced with permission from 
Hong EJ, Choi KC, Jeung E-B 2003 Maternal-fetal transfer of 
endocrine disruptors in the induction of Calbindin-D9k 
mRNA and protein during pregnancy in rat model. Mol Cell 
Endocrinol 212: 63–72]Reproductive Biology and Endocrinology 2005, 3:66 http://www.rbej.com/content/3/1/66
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BPA, diethylstilbestrol (DES) and E2 to be transferred
through breast milk from the dam to the neonate during
lactation via measuring the induction of CaBP-9k in uter-
ine tissue [14]. These results indicate that these com-
pounds have an estrogenic effect on the maternal uterus
during the lactation period, as shown by the induction of
both CaBP-9k mRNA and protein. There was a significant
increase in CaBP-9k mRNA in neonatal uterus when the
dams were treated with high doses of estrogenic com-
pounds, but protein levels of CaBP-9k were undetectable
(Fig. 4). Taken together, these findings suggest that mater-
nally injected estrogenic compounds may be transferred
to neonates through breast milk and thus, affect uterine
function, as shown by the induction of CaBP-9k gene
expression in neonatal uterus [14]. In addition, we
recently examined the effect of OP, NP and BPA on the
expression of CaBP-9k following maternal exposures dur-
ing late pregnancy in maternal and fetal uterus [15,41].
The expression of CaBP-9k mRNA was also induced fol-
lowing treatment with a high dose (600 mg/kg BW) of OP
transferred from mother exposed to fetuses during late
pregnancy and persisted in 5 day of lactation (Fig. 5). In
parallel with mRNA level, the expression level of CaBP-9k
protein was significantly induced by treatment with a high
dose of OP and NP in the maternal uterus by immunohis-
tochemistry (Fig. 6). In conclusion, the maternal expo-
sures to OP, NP and BPA during late pregnancy increased
the expression levels of CaBP-9k mRNA and protein in
maternal or neonatal uteri, suggesting that the absorption
and distribution of environmental estrogenic compounds
in maternal and neonatal uteri are extremely rapid, and
these chemicals can easily pass though placenta during
pregnancy to affect functions of neonatal reproductive tis-
sues [15,41]. In addition, a novel in vivo model was intro-
duced to detect both estrogenic and progestogenic
activities of EDs in the induction of CaBP-9k mRNA and
protein in the uterus of immature mice [35].
Genistein, a phytoestrogen, has been shown to have rela-
tively 20-fold higher binding affinity to the ERβ than ER
by a solid-phase binding assay [42]. To determine which
ER is involved in the induction of CaBP-9k  gene, we
employed genistein as a potent ERβ agonist to clarify its
effect on uterine CaBP-9k regulation [43]. Both CaBP-9k
mRNA and protein levels were significantly induced by
genistein in the uterus of immature rats. It is of interest
that the pre-treatment of immature rats with ICI 182,780
(ICI), followed by genistein or E2, completely blocked
α .
Localization of CaBP-9k protein by immunohistochemical- staining in maternal uterus Figure 6
Localization of CaBP-9k protein by immunohistochemical-
staining in maternal uterus. Immuno-reactivity of CaBP-9k 
protein expression following treatment with OP and NP was 
investigated in endometrium and smooth myometrial fibers 
dose-dependently. Especially, these proteins that are widely 
spaced through the stromal cells in endometrium s, stroma 
cells; le, Luminal epithelial cell; ge, glandular epithelial cell. 
Magnification × 100. [Reproduced with permission from 
Hong EJ, Choi KC, Jeung EB 2004 Induction of Calbindin-D9k 
mRNA and protein by maternal exposure to alkylphenols 
during late pregnancy in maternal and postnatal uteri of rats. 
Biol Reprod 71: 669–675]
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Effect of OP and NP on the induction of CaBP-9k mRNA in  neonatal uterus Figure 5
Effect of OP and NP on the induction of CaBP-9k mRNA in 
neonatal uterus. RT-PCR/Southern blot assay was performed 
during lactation period in neonatal uterus. The values repre-
sent means ± SD. a, P < 0.05 vs. vehicle. [Reproduced with 
permission from Hong EJ, Choi KC, Jeung EB 2004 Induction 
of Calbindin-D9k mRNA and protein by maternal exposure to 
alkylphenols during late pregnancy in maternal and postnatal 
uteri of rats. Biol Reprod 71: 669–675]Reproductive Biology and Endocrinology 2005, 3:66 http://www.rbej.com/content/3/1/66
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genistein- and E2-induced CaBP-9k protein in this tissue
as demonstrated in Fig. 7. In addition, genistein was dem-
onstrated to induce ERα protein, but not ERβ or PR
mRNA, an E2-responsive gene, in this tissue. These results
imply that genistein, an ERβ ligand, may regulate CaBP-9k
gene through ERα pathway and ERα may be a key media-
tor in the induction of uterine CaBP-9k gene in immature
rats [43]. To support an involvement of ERα-dependent
pathway by EDs, we demonstrated that uterine CaBP-9k
gene expression is mainly mediated by propyl pyrazole
triol (PPT), an ERα-selective ligand, in a dose- and time-
dependent manner, in the uterus of immature rats [44]. In
contrast, no significant alteration in the uterine CaBP-9k
gene was observed after diarylpropionitrile (DPN), an
ERβ-selective ligand. In addition, an estrogenicity of PPT
in inducing CaBP-9k expression was completely blocked
by ICI 182,780; which suggests that uterine CaBP-9k is
solely enhanced though ERα. Taken together, these results
indicate that uterine CaBP-9k is induced by E2 and endo-
crine disrupting chemicals via ERα pathway, but not ERβ,
in the uterus of immature rats [44].
Placental expression of CaBP-9k
Transport of Ca2+ through placenta is responsible for
developing fetus, and CaBP-9k appears to play an impor-
tant role in the regulation of Ca2+ from the mother to the
fetus during pregnancy. However, the role of CaBP-9k is
unknown to date in placenta during pregnancy. A recent
study demonstrated that CaBP-9k transcript is present in
cytotrophoblast cells and syncytiotrophoblasts of human
term placenta, with a lower expression in cytotrophoblast
cells as compared to syncytiotrophoblasts [45]. In addi-
tion, CaBP-9k protein was present in cytotrophoblast and
syncytiotrophoblast placental tissue sections as well as in
cultured cells, indicating that CaBP-9k is unequivocally
expressed by trophoblast cells from human term placenta
[45]. The expression of CaBP-9k gene has been investi-
gated in the placenta of other species [26,46-48]. The high
level of CaBP-9k has been localized to epithelial cells of
the yolk sac and endodermal cells of the placenta [16].
The expression of CaBP-9k mRNA was not detectable by
Northern blot analysis, while this transcript was detected
in porcine myometrium and placenta by RT-PCR [26]. As
previously described, CaBP-9k mRNA has been also local-
ized in the trophoblasts in various species. It is hypothe-
sized that CaBP-9k plays a role in calcium transfer and
fetal growth by parallel gestational changes in placental
CaBP-9k which reflects the fetal accumulation of calcium.
An increased level of CaBP-9k gene in the caruncular epi-
thelium during the last trimester is in response to the
increasing need for calcium to supply the fetal skeleton
with mineralization, suggesting that CaBP9k may play a
role in transporting calcium across the placenta in cattle
[48]. In the placenta of mice, the distinct regulation of
CaBP-9k has been demonstrated in the placenta com-
pared to other tissues such as intestine and kidney, indi-
cating that the expression of this gene is not dependent on
Vitamin D receptor [49]. Recently we demonstrated the
expression of CaBP-9k for the first time in mouse placenta
and extra-embryonic membrane separately, and CaBP-9k
mRNA may be regulated by sex steroid hormones (E2 and
P4) and their receptors through complex pathway in these
tissues [50].
Concluding Remarks
Although CaBP-9k is mainly expressed in female repro-
ductive tissues, i.e., uterus and placenta of various species,
the role of CaBP-9k remains unknown. It can be hypoth-
esized that uterine CaBP-9k may be involved in control-
ling myometrial activity related with intracellular calcium
level and placental CaBP-9k plays a role in calcium trans-
fer from the mother to the fetus for fetal growth. It appears
that CaBP-9k gene is not under the control of vitamin D
Effect of ICI on genistein-induced uterine CaBP-9k protein  expression Figure 7
Effect of ICI on genistein-induced uterine CaBP-9k protein 
expression. Immature rats were injected SC with ICI at 30 
min prior to genistein (40 mg/kg BW per day) or E2, and 
euthanized 24 h after final injection. The level of CaBP-9k 
protein was analyzed by immunoblot analysis. The values rep-
resent means ± SD. a, P < 0.05 vs. vehicle; b, P < 0.05 vs. gen-
istein or E2 treatment only [Reproduced with permission 
from Lee GS, Choi KC, Kim HJ, Jeung EB 2004 Effect of gen-
istein on the expression of Calbindin-D9k as a potential estro-
genic compound in the uterus of immature rats through 
estrogen receptors. Toxicol Sci 82: 451–457]Reproductive Biology and Endocrinology 2005, 3:66 http://www.rbej.com/content/3/1/66
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in the uterus despite the presence of vitamin D receptors
in this tissue; instead it is under the control of the sex ster-
oid hormones. The hormonal mechanism controlling
uterine CaBP-9k gene is relatively well understood in the
rat. In the uterus of rats, estrogen is known to up-regulate
and progesterone down-regulate the expression of CaBP-
9k gene during estrous cycle and pregnancy. However, the
recent studies demonstrated that CaBP-9k is mainly regu-
lated by progesterone, not estrogen in the uterus of mice
because of lack of responsiveness caused by a single-base
difference in the ERE of mouse CaBP-9k gene compared to
that of rats. Until now, a few studies demonstrated the
expression and regulation of CaBP-9k gene in the placenta
of various species. It appears that CaBP-9k mRNA may be
regulated by sex steroid hormones (E2 and P4) and their
receptors through complex pathway in these tissues. We
assumed that ERα may be a key mediator in uterine CaBP-
9k gene induction in immature rats. The elucidation of
other factors that regulate CaBP-9k mRNA will further
provide insight into the understanding of regulation of
CaBP-9k in these tissues, and its roles in the control of
reproductive functions.
The uterus is a highly estrogen-responsive tissue, which
can be measured through changes in CaBP-9k expression.
We demonstrated that the expression levels of CaBP-9k
mRNA and protein are induced by estrogenic chemicals,
so called "endocrine disruptors", in the uterus of imma-
ture rats. In addition, maternally injected estrogenic com-
pounds resulted in an increase of CaBP-9k mRNA and/or
protein in the fetal uterus during late pregnancy, suggest-
ing that placenta may not be a reliable barrier against
these estrogenic compounds for fetal health. It is of inter-
est that maternally injected estrogenic compounds may be
transferred to neonates through breast milk and thus
affect uterine function, as shown by the induction of
CaBP-9k gene expression in neonatal uterus. The expres-
sion of CaBP-9k mRNA and/or protein is an excellent
biomarker to detect an estrogenic chemical in the uterus
of immature rats which we developed and established.
Availability of this gene using immature rats will provide
an insight of risk assessment for estrogenic and pro-
gestogenic chemicals in our environment.
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